No black box warning on record for Droperidol

As of the latest FDA labeling reviewed, Droperidol (DROPERIDOL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Droperidol medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Droperidol should be administered with extreme caution in the presence of risk factors for development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with othe

No black box warning on record for Droperidol

Other warnings & precautions

WARNINGS Droperidol should be administered with extreme caution in the presence of risk factors for development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with othe

Droperidol Black Box Warning

No black box warning on record for Droperidol

Other warnings & precautions

Droperidol Black Box Warning

No black box warning on record for Droperidol

Other warnings & precautions